<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Mol Med</journal-id><journal-title-group><journal-title>Journal of Molecular Medicine (Berlin, Germany)</journal-title></journal-title-group><issn pub-type="ppub">0946-2716</issn><issn pub-type="epub">1432-1440</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19838659</article-id><article-id pub-id-type="publisher-id">549</article-id><article-id pub-id-type="doi">10.1007/s00109-009-0549-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>&#x003b1;- and &#x003b2;-Adducin polymorphisms affect podocyte proteins and proteinuria in rodents and decline of renal function in human IgA nephropathy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ferrandi</surname><given-names>Mara</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cusi</surname><given-names>Daniele</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Molinari</surname><given-names>Isabella</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Del Vecchio</surname><given-names>Lucia</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Barlassina</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Rastaldi</surname><given-names>Maria Pia</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Schena</surname><given-names>Francesco Paolo</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Macciardi</surname><given-names>Fabio</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Marcantoni</surname><given-names>Carmelita</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Roccatello</surname><given-names>Dario</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Peters</surname><given-names>Luanne L.</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Armelloni</surname><given-names>Silvia</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Min</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Giardino</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Mattinzoli</surname><given-names>Deborah</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Camisasca</surname><given-names>Claudio</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Palazzo</surname><given-names>Fiorentina</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Manunta</surname><given-names>Paolo</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Ferrari</surname><given-names>Patrizia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Bianchi</surname><given-names>Giuseppe</given-names></name><address><phone>+39-2-26435330</phone><fax>+39-2-26432384</fax><email>bianchi.giuseppe@hsr.it</email></address><xref ref-type="aff" rid="Aff12">12</xref></contrib><aff id="Aff1"><label>1</label>Prassis sigma-tau Research Institute, Settimo Milanese, Milan, Italy </aff><aff id="Aff2"><label>2</label>Graduate School of Nephrology, University of Milan, Milan, Italy </aff><aff id="Aff3"><label>3</label>Department of Medicine, Surgery and Dentistry, AO San Paolo, University of Milan, Milan, Italy </aff><aff id="Aff4"><label>4</label>Genomics and Bioinformatics Unit, Fondazione Filarete, Milan, Italy </aff><aff id="Aff5"><label>5</label>Department of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, Italy </aff><aff id="Aff6"><label>6</label>Laboratorio di Ricerca Nefrologica, Fondazione IRCCS Ospedale Maggiore Policlinico &#x00026; Fondazione D&#x02019;Amico per la Ricerca sulle Malattie Renali, Milan, Italy </aff><aff id="Aff7"><label>7</label>Division of Nephrology, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy </aff><aff id="Aff8"><label>8</label>Division of Nephrology, University Hospital, Verona, Italy </aff><aff id="Aff9"><label>9</label>Department of Medicine and Experimental Oncology, Clinical Pathology, University of Turin, Turin, Italy </aff><aff id="Aff10"><label>10</label>The Jackson Laboratory, Bar Harbor, ME USA </aff><aff id="Aff11"><label>11</label>Department of Psychiatry and Human Behavior, University of California, Irvine (UCI), Irvine, CA USA </aff><aff id="Aff12"><label>12</label>Division of Nephrology and Dialysis, Chair of Nephrology, San Raffaele Scientific Institute, Universit&#x000e0; &#x0201c;Vita-Salute&#x0201d; San Raffaele Hospital, Milan, Italy </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>10</month><year>2009</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>10</month><year>2009</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2010</year></pub-date><volume>88</volume><issue>2</issue><fpage>203</fpage><lpage>217</lpage><history><date date-type="received"><day>30</day><month>11</month><year>2008</year></date><date date-type="rev-recd"><day>20</day><month>9</month><year>2009</year></date><date date-type="accepted"><day>25</day><month>9</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2009</copyright-statement></permissions><abstract xml:lang="en"><p>Adducins are cytoskeletal actin-binding proteins (&#x003b1;, &#x003b2;, &#x003b3;) that function as heterodimers and heterotetramers and are encoded by distinct genes. Experimental and clinical evidence implicates &#x003b1;- and &#x003b2;-adducin variants in hypertension and renal dysfunction. Here, we have addressed the role of &#x003b1;- and &#x003b2;-adducin on glomerular function and disease using &#x003b2;-adducin null mice, congenic substrains for &#x003b1;- and &#x003b2;-adducin from the Milan hypertensive (MHS) and Milan normotensive (MNS) rats and patients with IgA nephropathy. Targeted deletion of &#x003b2;-adducin in mice reduced urinary protein excretion, preceded by an increase of podocyte protein expression (phospho-nephrin, synaptopodin, &#x003b1;-actinin, ZO-1, Fyn). The introgression of polymorphic MHS &#x003b2;-adducin locus into MNS (<italic>Add2</italic>, 529R) rats was associated with an early reduction of podocyte protein expression (nephrin, synaptopodin, &#x003b1;-actinin, ZO-1, podocin, Fyn), followed by severe glomerular and interstitial lesions and increased urinary protein excretion. These alterations were markedly attenuated when the polymorphic MHS &#x003b1;-adducin locus was also present (<italic>Add1</italic>, 316Y). In patients with IgA nephropathy, the rate of decline of renal function over time was associated to polymorphic &#x003b2;-adducin (ADD2, 1797T, <italic>rs4984</italic>) with a significant interaction with &#x003b1;-adducin (ADD1, 460W, <italic>rs4961</italic>). These findings suggest that adducin genetic variants participate in the development of glomerular lesions by modulating the expression of specific podocyte proteins.</p><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s00109-009-0549-x) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Adducin</kwd><kwd>Genetic renal disease</kwd><kwd>Glomerular disease</kwd><kwd>IgA nephropathy</kwd><kwd>Podocytes</kwd><kwd>Proteinuria</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2010</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Renal failure, triggered by a variety of factors, is a major and costly health care burden. After an apparently similar initial glomerular injury, large individual variations occur in the rate of progression toward renal failure as well as in the magnitude of urinary protein excretion, which is the major predictor of disease progression [<xref ref-type="bibr" rid="CR1">1</xref>]. Polymorphisms within genes encoding a few proteins associated with the podocyte actin cytoskeleton are responsible for glomerular proteinuria and progression toward failure in some monogenic and polygenic glomerular diseases [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>].</p><p>Adducin is a heterodimeric protein composed by &#x003b1;, &#x003b2;, and &#x003b3; subunits, encoded by distinct genes, that regulate actin polymerization and bundling as well as basic cellular functions involving the actin cytoskeleton, such as ion transport, cell motility, morphology, and adhesion [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Genetic variations within adducin genes have been shown to be involved in primary hypertension in rats and humans [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>To date, no link has been suggested between adducin polymorphisms and podocyte or glomerular function [<xref ref-type="bibr" rid="CR2">2</xref>]. Indeed, &#x003b1;- and &#x003b2;-adducin polymorphisms have been variously found to be associated with progression of renal failure in the presence of overt nephropathy or with decay of renal function in population studies [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>], although the results have not been consistent [<xref ref-type="bibr" rid="CR17">17</xref>]. Polymorphisms within the &#x003b1;- and &#x003b2;-adducin genes occur in rodents (&#x003b1;-adducin, <italic>Add1</italic>, F316Y; &#x003b2;-adducin, <italic>Add2</italic>, Q529R) [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>] and humans (&#x003b1;-adducin, ADD1, G460W, <italic>rs4961</italic> and S586C, <italic>rs4963</italic>; &#x003b2;-adducin, ADD2, C1797T, <italic>rs4984</italic>) [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], although at different positions, therefore different outcomes might be expected between species as function of these genetic variants. These observations call for a set of experimental and clinical approaches aimed at establishing whether these genetic variations within the &#x003b1;- and &#x003b2;-adducin genes are associated with changes in glomerular or podocyte function both in rodents and humans. This aim was pursued with the following three approaches to evaluate the impact of adducin variations across different contexts and to test to what extent rodent data may help in understanding human data: (1) the effect of the knockout of the &#x003b2;-adducin gene in mice on blood pressure, urinary protein excretion, and podocyte protein expression; (2) the effect of the introgression of a DNA segment, harboring the polymorphic &#x003b1;- and &#x003b2;-adducin loci from the Milan hypertensive rat strain (MHS) into the normotensive strain (MNS; congenic rat substrains) on blood pressure, urinary protein excretion, glomerular morphology, and function and podocyte protein expression; and (3) the association of &#x003b1;- and &#x003b2;-adducin genotypes with the rate of decline of renal function in patients with IgA nephropathy.</p><p>IgA nephropathy was selected as disease model for several reasons, among which: (1) it is the commonest glomerulonephritis worldwide, (2) its outcome is extremely variable, spanning from decades of normal renal function to fast progression toward end stage renal disease [<xref ref-type="bibr" rid="CR18">18</xref>], and (3) few clinical features have been detected as predictors of progression rate [<xref ref-type="bibr" rid="CR19">19</xref>].</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Animal models</title><p>All procedures for animal care were carried out in accordance with Prassis Institutional Guidelines. The care and husbandry of animals complied with the European Directives no 86/609 and with the Italian Law (DL116, January 27, 1992). The authorization for animal use in Prassis Laboratories was obtained from the Italian Health Authority. Animals had free access to the chow (standard diet, Altromin, Rieper, Italy) and to tap water and were maintained under controlled conditions of air temperature (22&#x02009;&#x000b1;&#x02009;2&#x000b0;C), relative humidity (50&#x02009;&#x000b1;&#x02009;15%), and day/night cycle (12&#x000a0;h): <list list-type="order"><list-item><p>&#x003b2;-Adducin (<italic>Add2</italic>) null mouse model: &#x003b2;-adducin knockout mice (official strain designation 129-Add2<sup>tm1Llp</sup>/Llp) have been previously described [<xref ref-type="bibr" rid="CR20">20</xref>]. Wild-type 129/Sv mice, carrying the same &#x003b2;-adducin polymorphism (Q529R) described in the MHS rats [<xref ref-type="bibr" rid="CR7">7</xref>], were used as controls.</p></list-item><list-item><p>Selection of congenic rat substrains from MHS and MNS parental strains: MHS, hypertensive, and MNS, normotensive, parental rats were derived from the internal stock colony (Prassis sigma-tau). Congenic rat strains were obtained from MHS hypertensive and MNS normotensive strains, as described [<xref ref-type="bibr" rid="CR21">21</xref>]. The donor strain was the MHS and the receiving genetic background was the MNS. The integrated physical and linkage map of the congenic segment indicated that the reciprocal congenics for &#x003b1;-adducin (<italic>Add1</italic>) contained a minimum/maximum of 1.0/8.8&#x000a0;Mb (6.6&#x000a0;cM) and that for &#x003b2;-adducin (<italic>Add2</italic>) a minimum/maximum of 1.0/26.4&#x000a0;Mb (13.5&#x000a0;cM) [<xref ref-type="bibr" rid="CR21">21</xref>].</p></list-item></list></p><p>Systolic blood pressure (SBP) and heart rate were recorded in conscious rats (from 2 to 6&#x000a0;months of age) and in mice (at 8 and 11&#x000a0;months) by an indirect tail-cuff plethysmographic method (BP recorder, U. Basile, Varese, Italy).</p></sec><sec id="Sec4"><title>Biochemical assays for urinary parameter measurements</title><p>Urinary parameters were measured in conscious male rats at 1.5, 3, 6, 8, and 11&#x000a0;months of age. Rats were housed in individual metabolic cages and had free access to water and food. Urinary parameters were also measured in conscious wild-type and knockout mice at 8 and 11&#x000a0;months of age. Mice received a bolus of 1&#x000a0;ml physiological solution by gavages, and urine was collected over a period of 6&#x000a0;h. Urine samples were analyzed for the following parameters: volume, pH, osmolality, Na<sup>+</sup> and K<sup>+</sup> concentrations (IL 943 photometer), total protein excretion (total protein Kit, Sentinel Diagnostics, Milan, Italy), and creatinine (colorimetric Kit, Sentinel Diagnostics).</p></sec><sec id="Sec5"><title>Histological and immunohistochemical studies</title><p>Renal tissue samples for light microscopy were fixed in 4% buffered paraformaldehyde and embedded in paraffin. Routine staining was performed on 2-&#x003bc;m-thick sections according to standard techniques [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p>For immunofluorescence and immunohistochemistry, unfixed renal tissue was embedded in OCT compound (Miles Scientific, Naperville, IL, USA), snap-frozen in a mixture of isopentane and dry-ice, and stored at &#x02212;80&#x000b0;C. Five-micrometer sections were placed on slides and fixed in cold acetone. In indirect immunofluorescence, the bound primary antibody was detected by Alexa Fluor 488 antirabbit or antimouse IgG (Invitrogen). For immunohistochemistry, after blocking endogenous biotin and endogenous peroxidase, the primary antibody was followed by an appropriate biotinylated secondary antibody and peroxidase-labeled streptavidin (both from Invitrogen), finally developed by diaminobenzidine (Sigma). Slides were mounted either with Vecta-shield aqueous mounting medium (Vector Laboratories, DBA Italia SRL) or with Bio Mount (Bio Optica, Milan, Italy).</p></sec><sec id="Sec6"><title>Glomeruli and podocyte isolation</title><p>Kidneys were taken from 7- to 10-day-old rats. Glomeruli were isolated by sieving then seeded in culture flasks precoated with collagen type IV (Sigma-Aldrich) at 37&#x000b0;C in 5% CO<sub>2</sub> atmosphere. On days 4 to 5, podocyte growth started, and by day 8, glomeruli were detached using trypsin&#x02013;EDTA and filtered through the 36-&#x003bc;m mesh to eliminate glomeruli. Second passage podocytes, &#x0003e;90% pure as judged by light microscopy, were seeded on flasks and chamber slides. Cell characterization was performed by immunofluorescence, using markers for podocytes (nephrin, podocin), epithelial (cytokeratin), smooth muscle (&#x003b1;-SMA), and endothelial cells (CD31).</p></sec><sec id="Sec7"><title>Western blotting</title><p>Samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, blotted and overnight incubated at 4&#x000b0;C with specific primary antibodies, followed by 1&#x000a0;h incubation with fluorescent secondary antibodies (Alexa Fluor), then analyzed and quantified by Odyssey Infrared Imaging Detection System (LI-COR Biosciences). Antibodies were anti-&#x003b1;- and anti-&#x003b2;-adducin (raised by S. Salardi in Prassis); anti-nephrin, anti-Fyn (Santa Cruz); anti-phospho-nephrin (kindly provided by Larry Holzman); anti-vimentin, anti-ZO-1, anti-&#x003b1;-SMA (Invitrogen); anti-synaptopodin (Progen Biotechnik); anti-&#x003b1;-actinin (Calbiochem); anti-podocin, anti-actin (Sigma-Aldrich); and anti-cytokeratin, anti-CD31 (Abcam).</p></sec><sec id="Sec8"><title>Human studies</title><p>Informed consent was obtained from all participants in the study, which was approved by the Ethical Committee of the San Raffaele Hospital, Milan, Italy.</p><p>Three hundred seventy-three patients, with biopsy proven primary IgA nephropathy (IgAN), were included in the study. Enrolling patients began in 1994 with the intent to recruit both incident cases and cases that were already being followed up. Only Caucasian patients of Italian origin were selected. The only selection criteria were willingness of the patient to participate and a follow-up longer or equal to 4&#x000a0;years. Clinical and anthropometric parameters, blood pressure values, and laboratory data at the time of renal biopsy were collected. After renal biopsy, all patients were followed up regularly with laboratory analyses and clinical evaluations (at least once per year) at their respective centers. Urinary protein excretion varies considerably from day to day, but average values remain fairly constant in IgAN, at least within the first 3&#x000a0;years after diagnosis [<xref ref-type="bibr" rid="CR23">23</xref>]; the average of the urinary protein excretion over the first 2&#x000a0;years after biopsy was therefore used for analysis. Glomerular filtration rate (GFR) was computed with the Cockcroft&#x02013;Gault formula [<xref ref-type="bibr" rid="CR24">24</xref>]. The individual rate of renal function decline was computed separately for each patient with the least squares method and expressed the loss of GFR per year (ml min<sup>&#x02212;1</sup> year<sup>&#x02212;1</sup>). Twenty-eight subjects were excluded because their data set was incomplete or their DNA failed to amplify and 17 because they showed a biphasic course of their GFR over time. Their renal function remained almost normal (serum creatinine less than 1.5&#x000a0;mg/dl) and stable for a variable number of years, before dropping abruptly with fast progression to end stage renal disease. We and others [<xref ref-type="bibr" rid="CR25">25</xref>] considered these cases as atypical.</p><p>The minimum number of GFR determinations used to compute progression rate was four per patient, while the average number of GFR values analyzed was 9.28&#x02009;&#x000b1;&#x02009;0.28 (8.74&#x02013;9.83, 95% confidence interval) per patient. Severity of renal damage according to Lee et al. [<xref ref-type="bibr" rid="CR26">26</xref>] was scored by two experienced pathologists, blind for patient's clinical features, outcome, and adducin genotype, with an interrater reproducibility higher than 90%. The grading system of Lee et al. consists of a single score (grades I to V) and summarizes glomerular and, to a lesser degree, interstitial lesions. Higher grades include crescent formation and interstitial fibrosis.</p></sec><sec id="Sec9"><title>Genotyping for &#x003b1;- and &#x003b2;-adducin</title><p>Genotyping was carried out on an ABI PRISM 7700 Sequence Detection System using the 5&#x02032; nuclease detection assay, as described [<xref ref-type="bibr" rid="CR27">27</xref>].</p></sec><sec id="Sec10"><title>Statistical analysis</title><p>Statistical analysis was performed with SPSS 16.0 (SPSS Inc., Chicago, IL, USA) and STATA 8 (Stata Corporation, College Station, TX, USA). Quantitative data were analyzed with Student's <italic>t</italic> test, one-way analysis of variance (ANOVA), or by simple or multiple linear regression when appropriate. A <italic>p</italic> value &#x0003c;0.05 (two-tailed) was considered significant. For human studies, progression rate was defined as the GFR decay each year (ml min<sup>&#x02212;1</sup> year<sup>&#x02212;1</sup>) in each individual subject. First simple linear regression models were tested with renal function loss as the dependent variable and, separately one for each model, urinary protein excretion, serum creatinine, serum IgA, body mass index (BMI), and hypertension at diagnosis, gender, age of onset, and severity grading of Lee et al. as independent variables. Then, the same variables were all entered in a multiple regression model in a stepwise procedure.</p><p>Test of genetic effects and interaction was performed with two-locus model fitting, and hypothesis testing was conducted via least squares regression analysis [<xref ref-type="bibr" rid="CR28">28</xref>]. The fit of the different genetic models (additive versus dominant) was compared and evaluated based on the respective <italic>F</italic> values of each model, and the one yielding the greatest <italic>F</italic> test was assumed to be the most appropriate. The effects of the various nongenetic factors considered above (urinary protein excretion, serum creatinine, serum IgA, BMI, hypertension at diagnosis, gender, age of onset, severity grading of Lee et al.) were tested using multivariate analysis, by including them as main effects as well as interaction with genotypes. The nonsignificant effects (all of the above, except urinary protein excretion) were discarded from the model in a stepwise procedure.</p><p>As most of the patients were recruited before generalized use of angiotensin-converting enzyme (ACE) inhibition, only about 47% of the subjects received an antihypertensive therapy, either ACE inhibitors (ACEI; 37%) or other drugs. This may affect the level of proteinuria. For this reason and for the fact that ACE inhibitor treatment was evenly distributed according to ADD1 (<inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ \chi_1^2 = 0.53 $$\end{document}</tex-math><inline-graphic xlink:href="109_2009_549_Article_IEq1.gif"/></alternatives></inline-formula>; <italic>p</italic>&#x02009;=&#x02009;0.46) and ADD2 (<inline-formula id="IEq2"><alternatives><tex-math id="M2">\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ \chi_1^2 = 0.80 $$\end{document}</tex-math><inline-graphic xlink:href="109_2009_549_Article_IEq2.gif"/></alternatives></inline-formula>; <italic>p</italic>&#x02009;=&#x02009;0.37) genotype, ACE inhibition was not accounted for in the multivariate analysis but analyzed separately.</p><p>The authors had full access to the data and take responsibility for its integrity. All authors have read and agreed to the manuscript as written.</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Localization of &#x003b1;- and &#x003b2;-adducin in the kidney</title><p>Immunostainings performed with specific anti-adducin antibodies in mice, rats, and humans revealed the presence of &#x003b1;- and &#x003b2;-adducin in renal glomeruli. Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> shows a typical immunofluorescence analysis of rat glomeruli. Immunogold electron microscopy (supplementary data, Fig. S<xref rid="MOESM1" ref-type="">1</xref>) in rat kidneys indicated that both proteins were ubiquitously present in glomerular cells. In particular, &#x003b1;- and &#x003b2;-adducins were present in podocytes. Reverse transcriptase polymerase chain reaction, immunogold, and Western blot analysis carried out in mouse, rat, and human podocytes confirmed the presence of mRNA and protein for &#x003b1;- and &#x003b2;-adducin isoforms (not shown). <fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Immunofluorescence analysis for &#x003b1;- and &#x003b2;-adducin localization in renal tissues. Immunostaining was performed on mouse, rat, and human renal sections by using specific anti-adducin antibodies and indicated the presence of &#x003b1;- and &#x003b2;-adducin in glomerular cells. The <italic>figure</italic> shows a typical indirect immunofluorescence (&#x000d7;400 magnification) of rat glomeruli</p></caption><graphic xlink:href="109_2009_549_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec13"><title>&#x003b2;-Adducin null mice</title><p><bold>Systolic blood pressure</bold> SBP did not differ between male and female &#x003b2;-adducin knockout mice and age- and sex-matched wild-type mice at 8 and 11&#x000a0;months of age. Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> shows SBP in 11-month-old mice. <fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Effect of &#x003b2;-adducin knockout on systolic blood pressure and proteinuria/creatinine ratio in mice. Indirect systolic blood pressure (<italic>upper</italic>) and urinary protein excretion normalized for urinary creatinine (<italic>lower</italic>) were measured in male and female wild-type (<italic>WT</italic>) and knockout (<italic>KO</italic>) mice at 8 and 11&#x000a0;months of age. Similar results have been obtained at the two ages. The <italic>figure</italic> shows the results at 11&#x000a0;months. Data are mean &#x000b1; SEM. Mouse numbers are indicated in the <italic>bars</italic>. **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 KO vs. WT</p></caption><graphic xlink:href="109_2009_549_Fig2_HTML" id="MO2"/></fig></p><p><bold>Renal studies</bold> No difference in urinary volume or Na<sup>+</sup>, K<sup>+</sup>, and creatinine excretion was detected between male and female knockout mice and wild-type controls at 8 and 11&#x000a0;months of age (not shown). However, compared to controls, male and female knockout mice showed a significant reduction of urinary protein excretion normalized for urinary creatinine excretion at both ages. Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> shows proteinuria/creatinine ratio in 11-month-old mice. Immunostaining of proteins belonging to podocyte slit diaphragm (such as nephrin and Fyn) and foot process cytoskeleton (such as synaptopodin, &#x003b1;-actinin, and ZO-1), performed in kidney sections from male 1.5-month-old wild-type and knockout mice, showed no &#x003b2;-adducin in knockout mice, a similar staining for &#x003b1;-adducin and nephrin but an increased staining for synaptopodin, &#x003b1;-actinin, ZO-1, and Fyn in knockout mice (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>; supplementary Fig. S<xref rid="MOESM1" ref-type="">2</xref>). <fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Immunofluorescence analysis of podocyte proteins and &#x003b1;- and &#x003b2;-adducin in mouse kidney sections. Immunohistochemical expression of podocyte proteins from slit diaphragm (nephrin, Fyn) and foot process cytoskeleton (synaptopodin, &#x003b1;-actinin, ZO-1) and &#x003b1;- and &#x003b2;-adducin was evaluated in kidney preparations from 1.5-month-old male wild-type and &#x003b2;-adducin knockout mice. Five mice for each group were investigated. Magnification: nephrin &#x000d7;1,000; synaptopodin &#x000d7;630; &#x003b1;-actinin WT &#x000d7;630; &#x003b1;-actinin KO &#x000d7;400; ZO-1 &#x000d7;400; Fyn &#x000d7;1,000; &#x003b1;- and &#x003b2;-adducin &#x000d7;400. Figure S<xref rid="MOESM1" ref-type="">2</xref> in supplementary data shows the quantitative immunofluorescence analysis</p></caption><graphic xlink:href="109_2009_549_Fig3_HTML" id="MO3"/></fig></p><p>A Western blot analysis, performed on isolated glomeruli of 1.5-month-old mice, showed no &#x003b2;-adducin in knockout mice and a similar content of &#x003b1;-adducin between the two groups (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Total nephrin was not different while phosphorylated nephrin was significantly increased in knockout mice, together with synaptopodin, &#x003b1;-actinin, ZO-1, and Fyn. Podocin and actin were similar between the two groups (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). The normalization of protein contents against actin did not change the pattern of differences between the two groups of mice. The supplementary Fig. S<xref rid="MOESM1" ref-type="">3</xref> shows the Western blots of the individual renal glomerular preparation from wild-type (<italic>n</italic>&#x02009;=&#x02009;5) and &#x003b2;-adducin knockout mice (<italic>n</italic>&#x02009;=&#x02009;5), probed with the specific antibodies. These data suggest that the reduced proteinuria observed in &#x003b2;-adducin knockout mice, as compared to wild-type controls, is preceded by an increased expression of specific podocyte marker proteins. <fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Western blot analysis of podocyte proteins in isolated glomeruli from &#x003b2;-adducin knockout mice. Renal glomeruli were isolated from 1.5-month-old male wild-type and &#x003b2;-adducin knockout mice. Five mice for each group were analyzed by Western blotting (10&#x000a0;&#x000b5;g protein/lane) using specific antibodies as indicated. The densitometric analysis is reported. The optical densities are expressed as arbitrary units. Data are mean &#x000b1; SEM. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 KO vs. WT. Figure S<xref rid="MOESM1" ref-type="">3</xref> in supplementary data shows the Western blots of the individual renal glomerular preparations from wild-type and &#x003b2;-adducin knockout mice</p></caption><graphic xlink:href="109_2009_549_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec14"><title>Congenic rat substrains for &#x003b1;- and &#x003b2;-adducin</title><p><bold>Systolic blood pressure</bold> As published [<xref ref-type="bibr" rid="CR21">21</xref>], the introgression of &#x003b1;-adducin from MHS into the MNS genetic background (NA congenic), but not that of &#x003b2;-adducin (NB congenic), significantly raises SBP in NA over MNS. Here, we have additionally demonstrated that in double-congenic strains (NAB), where polymorphic &#x003b1;- and &#x003b2;-adducin genes were simultaneously transferred from MHS into MNS rats, SBP did not differ from that of MNS at any age. Figure&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref> shows SBP at 3&#x000a0;months. These data suggest that, although &#x003b2;-adducin, per se, seems not to affect SBP, it blunts the hypertensive effect of &#x003b1;-adducin. <fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Systolic blood pressure and proteinuria/creatinine ratio in congenic rat substrains for &#x003b1;- and &#x003b2;-adducin. Indirect systolic blood pressure (<italic>left</italic>) and urinary protein excretion normalized for creatinine excretion (<italic>right</italic>) were measured in male parental hypertensive MHS and normotensive MNS rats and in congenic substrains obtained by introgressing &#x003b1;-adducin (<italic>NA</italic>), &#x003b2;-adducin (<italic>NB</italic>), and &#x003b1;&#x003b2;-adducin (<italic>NAB</italic>) from MHS into the MNS genetic background. The measurements have been done in rats at 3 (<italic>left</italic>) and 6 (<italic>right</italic>) months of age. Data are mean &#x000b1; SEM. Rat numbers are indicated in the <italic>bars</italic>. No variation of heart rate was observed in any congenic substrain as compared to MNS (not shown). *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 vs. MNS; $$<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. NB</p></caption><graphic xlink:href="109_2009_549_Fig5_HTML" id="MO5"/></fig></p><p><bold>Renal studies</bold> MNS rats develop an age-dependent glomerulosclerosis and proteinuria [<xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>] sustained by an increased glomerular production of thromboxane [<xref ref-type="bibr" rid="CR31">31</xref>], while MHS are protected from a glomerular damage. To assess the involvement of &#x003b1;- and &#x003b2;-adducin gene polymorphisms on the progression of renal alterations, urinary parameters were measured in rat strains at different ages (1.5, 3, 6, 8, 11&#x000a0;months). No urinary parameter (including 24&#x000a0;h urinary Na<sup>+</sup>, K<sup>+</sup>, creatinine, and proteinuria) differed among the various strains at 1.5 and 3&#x000a0;months of age (not shown). Protein excretion greatly increased with age in MNS and even more severely in NB, while it remained low over time in MHS, NA, and NAB. Figure&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref> shows proteinuria normalized for urinary creatinine excretion at 6&#x000a0;months of age. The values of proteinuria in rats are higher than in mice because of the presence of glomerulosclerosis in MNS rats [<xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>].</p><p>Histological studies, carried out in kidney preparations of rat strains at 3&#x000a0;months of age, showed normal glomeruli and normal interstitium (not shown), whereas at 6 and 11&#x000a0;months of age, glomerular and interstitial damage paralleled the increase of proteinuria in MNS as compared to MHS (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). In NB, where a massive proteinuria was observed (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>), histological alterations (mesangial proliferation, mesangial matrix expansion, segmental glomerulosclerosis, interstitial leukocyte infiltration, focal areas of interstitial fibrosis, tubular dilation and giant tubular protein casts), were even more severe than in MNS rats (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). Conversely, no histological alteration was observed in MHS, NA, and NAB strains, where MHS &#x003b1;-adducin was present (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). The supplementary Fig. S<xref rid="MOESM1" ref-type="">4</xref> shows the quantitative morphometric analysis of histological data obtained from five rats per group. Electron microscopy, carried out in 3-month-old rats, confirmed the presence of podocyte foot process effacement in MNS and NB, while NA appeared protected (supplementary Fig. S<xref rid="MOESM1" ref-type="">5</xref>). <fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>Glomerular morphologic analysis in kidneys from congenic rat substrains for &#x003b1;- and &#x003b2;-adducin. Histomorphological studies have been conducted in kidney preparations from male parental hypertensive MHS and normotensive MNS rats and in congenic substrains for &#x003b1;-adducin (<italic>NA</italic>), &#x003b2;-adducin (<italic>NB</italic>), and &#x003b1;&#x003b2;-adducin (<italic>NAB</italic>). The analysis has been performed in rats at 6&#x000a0;months of age. The increased urinary protein excretion of MNS, which was even higher in NB, paralleled the appearance of glomerular and interstitial alterations as described in the text. The presence of MHS &#x003b1;-adducin in MHS, NA, and NAB appeared to protect against proteinuria and glomerular damage. Five rats for each group were analyzed. Magnification: MHS and NAB &#x000d7;400; MNS, NA, and NB &#x000d7;250. Figure S<xref rid="MOESM1" ref-type="">4</xref> in supplementary data shows the quantitative morphometric analysis</p></caption><graphic xlink:href="109_2009_549_Fig6_HTML" id="MO6"/></fig></p><p>The immunohistochemical expression of podocyte proteins, evaluated in kidney preparations from 1.5-month-old rats, where no difference in proteinuria was present among all strains, showed a decreased expression of nephrin, synaptopodin, &#x003b1;-actinin (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>), ZO-1, Fyn (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>), P-cadherin (not shown), and &#x003b1;-adducin (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9</xref>) in MNS and NB strains as compared to MHS, NA, and NAB. Conversely, &#x003b2;-adducin (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9</xref>) and vimentin (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>), a microfilament localized in the podocyte cell body, were normally expressed in all strains. The supplementary Figs. S<xref rid="MOESM1" ref-type="">6</xref> and S<xref rid="MOESM1" ref-type="">7</xref> show the quantitative analysis of these data obtained from five rats per group. Note that &#x003b1;-adducin, but not &#x003b2;-adducin, was less expressed in MNS and NB (Fig. S7). <fig id="Fig7"><label>Fig.&#x000a0;7</label><caption><p>Immunofluorescence analysis of podocyte proteins in kidney sections from congenic rat substrains for &#x003b1;- and &#x003b2;-adducin. Immunohistochemical expression of podocyte proteins (nephrin, synaptopodin, &#x003b1;-actinin) was evaluated in kidney preparations from 1.5-month-old male MHS, MNS rats and in congenic substrains for &#x003b1;-adducin (<italic>NA</italic>), &#x003b2;-adducin (<italic>NB</italic>), and &#x003b1;&#x003b2;-adducin (<italic>NAB</italic>). Five rats for each group were analyzed. Magnification: nephrin MHS and NA &#x000d7;250; nephrin MNS, NB, and NAB &#x000d7;400; synaptopodin and &#x003b1;-actinin &#x000d7;400. Figure S<xref rid="MOESM1" ref-type="">6</xref> in supplementary data shows the quantitative immunofluorescence analysis</p></caption><graphic xlink:href="109_2009_549_Fig7_HTML" id="MO7"/></fig><fig id="Fig8"><label>Fig.&#x000a0;8</label><caption><p>Immunofluorescence analysis of podocyte proteins in kidney sections from congenic rat substrains for &#x003b1;- and &#x003b2;-adducin. Immunohistochemical expression of podocyte proteins (ZO-1, Fyn, vimentin) was evaluated in kidney preparations from 1.5-month-old male MHS, MNS rats and in congenic substrains for &#x003b1;-adducin (<italic>NA</italic>), &#x003b2;-adducin (<italic>NB</italic>), and &#x003b1;&#x003b2;-adducin (<italic>NAB</italic>). Five rats for each group were analyzed. Magnification: ZO-1, Fyn, vimentin &#x000d7;400. Figure S<xref rid="MOESM1" ref-type="">6</xref> in supplementary data shows the quantitative immunofluorescence analysis</p></caption><graphic xlink:href="109_2009_549_Fig8_HTML" id="MO8"/></fig><fig id="Fig9"><label>Fig.&#x000a0;9</label><caption><p>Immunofluorescence analysis of &#x003b1;- and &#x003b2;-adducin in kidney sections from congenic rat substrains. Immunohistochemical expression of &#x003b1;- and &#x003b2;-adducin was evaluated in kidney preparations from 1.5-month-old male MHS, MNS rats and in congenic substrains for &#x003b1;-adducin (<italic>NA</italic>), &#x003b2;-adducin (<italic>NB</italic>), and &#x003b1;&#x003b2;-adducin (<italic>NAB</italic>). Five rats for each group were analyzed (&#x000d7;400 magnification). Figure S<xref rid="MOESM1" ref-type="">7</xref> in supplementary data shows the quantitative immunofluorescence analysis</p></caption><graphic xlink:href="109_2009_549_Fig9_HTML" id="MO9"/></fig></p><p>A Western blot analysis of isolated glomeruli from 25- to 45-day-old rats showed a similar content of actin but a reduced expression of nephrin, either normalized or not against actin, in MNS and NB as compared to MHS, NA, and NAB rats (Fig.&#x000a0;<xref rid="Fig10" ref-type="fig">10</xref>). The supplementary Fig. S<xref rid="MOESM1" ref-type="">8</xref> shows the Western blots for nephrin and actin of the individual renal glomerular preparations from rat substrains. Five rats per group were analyzed. <fig id="Fig10"><label>Fig.&#x000a0;10</label><caption><p>Western blot analysis of nephrin and actin in isolated glomeruli from congenic rat substrains for &#x003b1;- and &#x003b2;-adducin. Renal glomeruli were isolated from 25&#x02013;45-day-old male MHS, MNS rats and congenic substrains for &#x003b1;-adducin (<italic>NA</italic>), &#x003b2;-adducin (<italic>NB</italic>), and &#x003b1;&#x003b2;-adducin (<italic>NAB</italic>). Five rats for each group were analyzed by Western blotting (10&#x000a0;&#x000b5;g protein/lane) using specific antibodies against nephrin and actin. The densitometric analysis is reported as arbitrary units. Data are mean &#x000b1; SEM. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. MNS. Figure S<xref rid="MOESM1" ref-type="">8</xref> in supplementary data shows the Western blots for nephrin and actin of the individual renal glomerular preparations from rat substrains</p></caption><graphic xlink:href="109_2009_549_Fig10_HTML" id="MO10"/></fig></p><p>Furthermore, a Western blot analysis of some podocyte markers, performed on primary cultures of glomerular podocytes from 10-day-old rats, confirmed a decreased expression of nephrin, &#x003b1;-actinin, ZO-1, podocin, and &#x003b1;-adducin in MNS and NB compared to NA podocytes (Fig.&#x000a0;<xref rid="Fig11" ref-type="fig">11</xref>). Conversely, &#x003b2;-adducin (supplementary Fig. S<xref rid="MOESM1" ref-type="">9</xref>) and actin expression (Fig.&#x000a0;<xref rid="Fig11" ref-type="fig">11</xref>) was similar among the three groups. The normalization of protein contents against actin did not change the pattern of differences among the three groups of rats. The supplementary Fig. S<xref rid="MOESM1" ref-type="">9</xref> shows the Western blots of the individual glomerular podocyte preparations from congenic rats. <fig id="Fig11"><label>Fig.&#x000a0;11</label><caption><p>Glomerular podocyte cultures from MNS rats and congenic substrains for &#x003b1;-adducin (<italic>NA</italic>) and &#x003b2;-adducin (<italic>NB</italic>). Neonatal rats (&#x0003c;10&#x000a0;days old) were used for podocyte culture preparations that were analyzed by Western blotting (10&#x000a0;&#x000b5;g protein/lane) using specific antibodies as indicated. Four preparations from MNS and NA and seven from NB rats were analyzed. The densitometric analysis is reported. The optical densities are expressed as arbitrary units. Data are mean &#x000b1; SEM. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 vs. MNS. Figure S<xref rid="MOESM1" ref-type="">9</xref> in supplementary data shows the Western blots of the individual glomerular podocyte preparations from rat substrains</p></caption><graphic xlink:href="109_2009_549_Fig11_HTML" id="MO11"/></fig></p><p>The present findings suggest that the pronounced proteinuria in MNS and NB strains, carrying the &#x003b2;-adducin genetic variant, is preceded by an early alteration of podocyte protein expression responsible for the changes of the glomerular filtration barrier permeability associated with protein leakage. Conversely, the MHS &#x003b1;-adducin variant seems to be protective in MHS, NA, and NAB rats.</p></sec><sec id="Sec15"><title>Renal function loss in patients with IgA nephropathy</title><p>Baseline data of the total sample are reported in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. At univariate analysis, urinary protein excretion (<italic>R</italic><sup>2</sup>&#x02009;=&#x02009;0.214, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), hypertension (<italic>R</italic><sup>2</sup>&#x02009;=&#x02009;0.103, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), serum creatinine (<italic>R</italic><sup>2</sup>&#x02009;=&#x02009;0.036, <italic>p</italic>&#x02009;=&#x02009;0.001) at diagnosis and score of Lee et al. (<italic>R</italic><sup>2</sup>&#x02009;=&#x02009;0.066, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) correlated significantly with renal function loss, while age of onset, serum IgA concentration, gender, and BMI did not. When all were included in a multiple regression model, only urinary protein excretion and hypertension at diagnosis gave an independent significant contribution to the model. The overall variance increased very little from that explained by proteinuria alone (<italic>R</italic><sup>2</sup> from 0.214 to 0.237), with only minimal contribution from hypertension at diagnosis (<italic>R</italic><sup>2</sup>&#x02009;=&#x02009;0.023, <italic>p</italic>&#x02009;=&#x02009;0.002). <table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Baseline patient demographics, clinical and laboratory data</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Mean (range) &#x000b1; SEM</th></tr></thead><tbody><tr><td>Age at presentation (years)</td><td>31.51 (16&#x02013;77)&#x02009;&#x000b1;&#x02009;0.77</td></tr><tr><td>Age at biopsy (years)</td><td>34.73 (16&#x02013;77)&#x02009;&#x000b1;&#x02009;0.79</td></tr><tr><td>Males (% men)</td><td>247 (75.3%)</td></tr><tr><td>Hypertensive (%)</td><td>158 (48.2%)</td></tr><tr><td>Antihypertensive treatment (%)</td><td>152 (46.3%)</td></tr><tr><td>Macrohematuria (%)</td><td>143 (43.6%)</td></tr><tr><td>Body weight (kg)</td><td>70.21&#x02009;&#x000b1;&#x02009;0.84</td></tr><tr><td>Height (cm)</td><td>169.25&#x02009;&#x000b1;&#x02009;2.05</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>24.36&#x02009;&#x000b1;&#x02009;0.22</td></tr><tr><td>Serum creatinine (mg/dl)</td><td>1.51&#x02009;&#x000b1;&#x02009;0.07</td></tr><tr><td>Creatinine clearance (ml/min)<sup>a</sup></td><td>80.40&#x02009;&#x000b1;&#x02009;2.0</td></tr><tr><td>SBP (mmHg)</td><td>136.39&#x02009;&#x000b1;&#x02009;1.05</td></tr><tr><td>DBP (mmHg)</td><td>87.55&#x02009;&#x000b1;&#x02009;0.67</td></tr><tr><td>Urinary protein excretion (g/24&#x000a0;h)</td><td>1.46&#x02009;&#x000b1;&#x02009;0.07</td></tr><tr><td>Follow-up from presentation (years)</td><td>11.36 (4&#x02013;23)&#x02009;&#x000b1;&#x02009;0.38</td></tr><tr><td>Follow-up from biopsy (years)</td><td>8.44 (4&#x02013;19)&#x02009;&#x000b1;&#x02009;0.37</td></tr><tr><td>Renal function loss (ml/min&#x000a0;year)</td><td>&#x02212;5.46&#x02009;&#x000b1;&#x02009;0.42</td></tr></tbody></table><table-wrap-foot><p>If not otherwise indicated, reported data are the ones collected at the time of renal biopsy. Presentation means the first recorded/reported episode of macrohematuria or microhematuria/proteinuria at urinalysis</p><p><sup>a</sup>Computed with Cockcroft&#x02013;Gault formula [<xref ref-type="bibr" rid="CR24">24</xref>]</p></table-wrap-foot></table-wrap></p><p>The frequencies of ADD1 (&#x003b1;-adducin) and ADD2 (&#x003b2;-adducin) genotypes are summarized in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. Clinical characteristics according to ADD1 and ADD2 genotype are reported in Tables&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> and <xref rid="Tab4" ref-type="table">4</xref>, respectively. Carriers of at least one ADD2 1797T allele had slightly higher blood pressure. The degree of renal function loss was affected by ADD2 (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>), but not by ADD1 genotypes (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). <table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Distribution of ADD1 (&#x003b1;-adducin) and ADD2 (&#x003b2;-adducin) genotypes</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2">ADD1</th><th colspan="2">ADD2</th></tr></thead><tbody><tr><td>Gly460Gly</td><td char="(" align="char">231 (70.4%)</td><td>C1797C</td><td char="(" align="char">217 (66.2%)</td></tr><tr><td>Gly460Trp</td><td char="(" align="char">85 (25.9%)</td><td>C1797T</td><td char="(" align="char">95 (29.0%)</td></tr><tr><td>Trp460Trp</td><td char="(" align="char">12 (3.7%)</td><td>T1797T</td><td char="(" align="char">16 (4.9%)</td></tr></tbody></table><table-wrap-foot><p>Genotype frequencies are in Hardy&#x02013;Weinberg equilibrium (test for deviation from Hardy&#x02013;Weinberg: <italic>p</italic>&#x02009;=&#x02009;0.826 for ADD1 and <italic>p</italic>&#x02009;=&#x02009;0.841 for ADD2)</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Baseline patient demographics, clinical and laboratory data according to ADD1 (&#x003b1;-adducin) genotype</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th>Gly460Gly (231)</th><th>460Trp (97)</th><th rowspan="2"><italic>p</italic></th></tr><tr><th>Mean (range) &#x000b1; SEM</th><th>Mean (range) &#x000b1; SEM</th></tr></thead><tbody><tr><td>Age at presentation (years)</td><td>31.5 (16&#x02013;77)&#x02009;&#x000b1;&#x02009;0.91</td><td>31.6 (15&#x02013;72)&#x02009;&#x000b1;&#x02009;1.42</td><td>n.s.</td></tr><tr><td>Age at biopsy (years)</td><td>34.8 (16&#x02013;77)&#x02009;&#x000b1;&#x02009;0.95</td><td>34.6 (17&#x02013;72)&#x02009;&#x000b1;&#x02009;1.43</td><td>n.s.</td></tr><tr><td>Males (% men)</td><td>175 (76%)</td><td>72 (74%)</td><td>n.s.</td></tr><tr><td>Hypertensive (%)</td><td>144 (62%)</td><td>44 (45%)</td><td>n.s.</td></tr><tr><td>Antihypertensive treatment (%)</td><td>108 (47%)</td><td>44 (45%)</td><td>n.s.</td></tr><tr><td>Macrohematuria (%)</td><td>94 (41%)</td><td>49 (50%)</td><td>n.s.</td></tr><tr><td>Body weight (kg)</td><td>70.3&#x02009;&#x000b1;&#x02009;0.71</td><td>70.1&#x02009;&#x000b1;&#x02009;1.02</td><td>n.s.</td></tr><tr><td>Height (cm)</td><td>169.4&#x02009;&#x000b1;&#x02009;0.56</td><td>168.8&#x02009;&#x000b1;&#x02009;0.76</td><td>n.s.</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>24.3&#x02009;&#x000b1;&#x02009;0.20</td><td>24.5&#x02009;&#x000b1;&#x02009;0.32</td><td>n.s.</td></tr><tr><td>Serum creatinine (mg/dl)</td><td>1.52&#x02009;&#x000b1;&#x02009;0.10</td><td>1.47&#x02009;&#x000b1;&#x02009;0.08</td><td>n.s.</td></tr><tr><td>Creatinine clearance (ml/min)<sup>a</sup></td><td>81.0&#x02009;&#x000b1;&#x02009;2.24</td><td>79.0&#x02009;&#x000b1;&#x02009;3.90</td><td>n.s.</td></tr><tr><td>SBP (mmHg)</td><td>135.8&#x02009;&#x000b1;&#x02009;1.20</td><td>137.7&#x02009;&#x000b1;&#x02009;1.90</td><td>n.s.</td></tr><tr><td>DBP (mmHg)</td><td>87.2&#x02009;&#x000b1;&#x02009;0.80</td><td>88.5&#x02009;&#x000b1;&#x02009;1.22</td><td>n.s.</td></tr><tr><td>Urinary protein excretion (g/24&#x000a0;h)</td><td>1.47&#x02009;&#x000b1;&#x02009;0.08</td><td>1.46&#x02009;&#x000b1;&#x02009;0.15</td><td>n.s.</td></tr><tr><td>Follow-up from presentation (years)</td><td>11.3 (4&#x02013;23)&#x02009;&#x000b1;&#x02009;0.35</td><td>11.4 (4&#x02013;23)&#x02009;&#x000b1;&#x02009;0.55</td><td>n.s.</td></tr><tr><td>Follow-up from biopsy (years)</td><td>8.3 (4&#x02013;19)&#x02009;&#x000b1;&#x02009;0.30</td><td>8.7 (4&#x02013;19)&#x02009;&#x000b1;&#x02009;0.49</td><td>n.s.</td></tr><tr><td>Renal function loss (ml/min&#x000a0;year)</td><td>&#x02212;5.04&#x02009;&#x000b1;&#x02009;0.42</td><td>&#x02212;6.46&#x02009;&#x000b1;&#x02009;1.00</td><td>n.s.</td></tr></tbody></table><table-wrap-foot><p>If not otherwise indicated, reported data are the ones collected at the time of renal biopsy. Presentation means the first recorded/reported episode of macrohematuria or microhematuria/proteinuria at urinalysis</p><p><sup>a</sup>Computed with Cockcroft&#x02013;Gault formula [<xref ref-type="bibr" rid="CR24">24</xref>]</p></table-wrap-foot></table-wrap><table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Baseline patient demographics, clinical and laboratory data according to ADD2 (&#x003b2;-adducin) genotype</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th>C1797C (217)</th><th>1797T (111)</th><th rowspan="2"><italic>p</italic></th></tr><tr><th>Mean (range) &#x000b1; SEM</th><th>Mean (range) &#x000b1; SEM</th></tr></thead><tbody><tr><td>Age at presentation (years)</td><td>31.5 (16&#x02013;77)&#x02009;&#x000b1;&#x02009;0.95</td><td>31.6 (16&#x02013;72)&#x02009;&#x000b1;&#x02009;1.31</td><td>n.s.</td></tr><tr><td>Age at biopsy (years)</td><td>34.9 (16&#x02013;77)&#x02009;&#x000b1;&#x02009;0.99</td><td>34.4 (16&#x02013;72)&#x02009;&#x000b1;&#x02009;1.33</td><td>n.s.</td></tr><tr><td>Males (% men)</td><td>168 (77%)</td><td>79 (71%)</td><td>n.s.</td></tr><tr><td>Hypertensive (%)</td><td>99 (46%)</td><td>59 (53%)</td><td>n.s.</td></tr><tr><td>Antihypertensive treatment (%)</td><td>94 (43%)</td><td>58 (52%)</td><td>n.s.</td></tr><tr><td>Macrohematuria (%)</td><td>102 (47%)</td><td>41 (37%)</td><td>n.s.</td></tr><tr><td>Body weight (kg)</td><td>70.9&#x02009;&#x000b1;&#x02009;0.72</td><td>68.9&#x02009;&#x000b1;&#x02009;1.00</td><td>n.s.</td></tr><tr><td>Height (cm)</td><td>169.4&#x02009;&#x000b1;&#x02009;0.53</td><td>168.8&#x02009;&#x000b1;&#x02009;0.80</td><td>n.s.</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>24.5&#x02009;&#x000b1;&#x02009;0.22</td><td>23.9&#x02009;&#x000b1;&#x02009;0.27</td><td>n.s.</td></tr><tr><td>Serum creatinine (mg/dl)</td><td>1.48&#x02009;&#x000b1;&#x02009;0.07</td><td>1.56&#x02009;&#x000b1;&#x02009;0.16</td><td>n.s.</td></tr><tr><td>Creatinine clearance (ml/min)<sup>a</sup></td><td>82.2&#x02009;&#x000b1;&#x02009;2.51</td><td>76.9&#x02009;&#x000b1;&#x02009;3.02</td><td>n.s.</td></tr><tr><td>SBP (mmHg)</td><td>134.8&#x02009;&#x000b1;&#x02009;1.12</td><td>139.5&#x02009;&#x000b1;&#x02009;2.01</td><td>0.041</td></tr><tr><td>DBP (mmHg)</td><td>86.6&#x02009;&#x000b1;&#x02009;0.78</td><td>89.3&#x02009;&#x000b1;&#x02009;1.22</td><td>0.054</td></tr><tr><td>Urinary protein excretion (g/24&#x000a0;h)</td><td>1.38&#x02009;&#x000b1;&#x02009;0.09</td><td>1.63&#x02009;&#x000b1;&#x02009;0.13</td><td>n.s.</td></tr><tr><td>Follow-up from presentation (years)</td><td>11.4 (4&#x02013;23)&#x02009;&#x000b1;&#x02009;0.34</td><td>11.3 (4&#x02013;21)&#x02009;&#x000b1;&#x02009;0.58</td><td>n.s.</td></tr><tr><td>Follow-up from biopsy (years)</td><td>8.4 (4&#x02013;19)&#x02009;&#x000b1;&#x02009;0.24</td><td>8.6 (4&#x02013;19)&#x02009;&#x000b1;&#x02009;0.49</td><td>n.s.</td></tr><tr><td>Renal function loss (ml/min&#x000a0;year)</td><td>&#x02212;4.77&#x02009;&#x000b1;&#x02009;0.41</td><td>&#x02212;6.82&#x02009;&#x000b1;&#x02009;0.92</td><td>0.043</td></tr></tbody></table><table-wrap-foot><p>If not otherwise indicated, reported data are the ones collected at the time of renal biopsy. Presentation means the first recorded/reported episode of macrohematuria or microhematuria/proteinuria at urinalysis</p><p><sup>a</sup>Computed with Cockcroft&#x02013;Gault formula [<xref ref-type="bibr" rid="CR24">24</xref>]</p></table-wrap-foot></table-wrap></p><p>The ANOVA table for the model, considering ADD1 460Trp allele and ADD2 1797T allele dominant, is shown in Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>. The <italic>R</italic><sup>2</sup> for the model, including the effect of urinary protein excretion at diagnosis, was 0.245. When only ADD1 and ADD2 genotypes and their interaction were included, the model remained statistically significant, though the variance explained was substantially lower (<italic>R</italic><sup>2</sup>&#x02009;=&#x02009;0.057, <italic>p</italic>&#x02009;=&#x02009;0.0004). Note that also ADD1&#x02013;ADD2 interaction was statistically significant (<italic>p</italic>&#x02009;=&#x02009;0.0174). <table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>ANOVA for statistical model used to test effects of interactions among ADD1 (&#x003b1;-adducin) and ADD2 (&#x003b2;-adducin) genotypes</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Source</th><th>&#x003b2;</th><th>std err &#x003b2;</th><th colspan="2">[95% Conf. Interval]</th><th><italic>F</italic> value</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>Proteinuria</td><td char="." align="char">&#x02212;2.24</td><td char="." align="char">0.329</td><td char="." align="char">&#x02212;2.892</td><td char="." align="char">&#x02212;1.595</td><td char="." align="char">43.36</td><td char="." align="char">&#x0003c;0.0001</td></tr><tr><td>Follow-up after biopsy (years)</td><td char="." align="char">0.27</td><td char="." align="char">0.098</td><td char="." align="char">0.083</td><td char="." align="char">0.471</td><td char="." align="char">7.94</td><td char="." align="char">0.0052</td></tr><tr><td>&#x003b1;-Adducin (460Trp allele dominant)</td><td char="." align="char">&#x02212;0.15</td><td char="." align="char">1.091</td><td char="." align="char">&#x02212;2.301</td><td char="." align="char">1.994</td><td char="." align="char">4.27</td><td char="." align="char">0.0397</td></tr><tr><td>&#x003b2;-Adducin (1797T allele dominant)</td><td char="." align="char">&#x02212;4.66</td><td char="." align="char">1.490</td><td char="." align="char">&#x02212;7.594</td><td char="." align="char">&#x02212;1.728</td><td char="." align="char">8.28</td><td char="." align="char">0.0043</td></tr><tr><td>Adducin interaction</td><td char="." align="char">4.45</td><td char="." align="char">1.863</td><td char="." align="char">0.787</td><td char="." align="char">8.117</td><td char="." align="char">4.93</td><td char="." align="char">0.0092</td></tr></tbody></table><table-wrap-foot><p>Dependent variable: eGFR loss (ml/min&#x000a0;year)</p></table-wrap-foot></table-wrap></p><p>Neither ADD1 nor ADD2 was associated to proteinuria. However, only in carriers of the adducin mutant alleles, ACE inhibitors significantly decreased the level of proteinuria (ADD1 460Trp 1.87&#x02009;&#x000b1;&#x02009;0.24 versus 1.18&#x02009;&#x000b1;&#x02009;0.17&#x000a0;g/24&#x000a0;h, <italic>p</italic>&#x02009;=&#x02009;0.02; ADD2 1797T 1.96&#x02009;&#x000b1;&#x02009;0.2 versus 1.14&#x02009;&#x000b1;&#x02009;0.17&#x000a0;g/24&#x000a0;h, <italic>p</italic>&#x02009;=&#x02009;0.04). Conversely, in carriers of the adducin wild-type alleles, ACE inhibitors did not affect proteinuria (ADD1 Gly460Gly 1.63&#x02009;&#x000b1;&#x02009;0.12 versus 1.38&#x02009;&#x000b1;&#x02009;0.11&#x000a0;g/24&#x000a0;h, <italic>p</italic>&#x02009;=&#x02009;0.15; ADD2 C1797C 1.56&#x02009;&#x000b1;&#x02009;0.13 versus 1.28&#x02009;&#x000b1;&#x02009;0.11&#x000a0;g/24&#x000a0;h, <italic>p</italic>&#x02009;=&#x02009;0.13).</p><p>To provide more information on the relationships between GFR loss per year, genotypes, and level of proteinuria at onset, these variables were analyzed with an additional linear model in which the degree of proteinuria was analyzed as tertiles, and least square means were obtained for the rate of renal function loss in each of these classes. The rate of renal function decline was more than double in carriers of the ADD1 460Trp + ADD2 1797T combination of genotypes (&#x02212;4.04&#x02009;&#x000b1;&#x02009;1.15&#x000a0;ml&#x000a0;min<sup>&#x02212;1</sup>&#x02009;year<sup>&#x02212;1</sup> per gram of urinary protein) than in carriers of the ADD1 Gly460Gly + ADD2 C1797C one (&#x02212;1.64&#x02009;&#x000b1;&#x02009;0.36&#x000a0;ml&#x000a0;min<sup>&#x02212;1</sup>&#x02009;year<sup>&#x02212;1</sup>; <italic>p</italic>&#x02009;=&#x02009;0.005), with intermediate and similar values for the combinations where only one mutant adducin (either ADD1 or ADD2) genotype was present (Gly460Gly&#x02009;+&#x02009;1797T &#x02212;3.04&#x02009;&#x000b1;&#x02009;0.57&#x000a0;ml&#x000a0;min<sup>&#x02212;1</sup>&#x02009;year<sup>&#x02212;1</sup>; 460Trp&#x02009;+&#x02009;C1797C &#x02212;3.09&#x02009;&#x000b1;&#x02009;0.44&#x000a0;ml&#x000a0;min<sup>&#x02212;1</sup>&#x02009;year<sup>&#x02212;1</sup>).</p><p><bold>Glomerular immunohistochemical analysis for &#x003b1;- and &#x003b2;-adducin in IgA nephropathy</bold> Twenty IgAN patients, chosen for the availability of the material for immunohistochemistry, have been analyzed and divided into two groups according to the rate of renal function decline: stable renal function (nonprogressors) or rapidly progressing toward end-stage renal failure (progressors). We did not find any difference in &#x003b1;- and &#x003b2;-adducin staining. The results of two representative patients are shown in the supplementary Fig. S<xref rid="MOESM1" ref-type="">10</xref>.</p></sec></sec><sec id="Sec16"><title>Discussion</title><p>The major findings described in the present work are (1) the localization of &#x003b1;- and &#x003b2;-adducin in glomerular podocytes in mice, rats, and humans; (2) in &#x003b2;-adducin null mice, compared to wild-type controls, carrying the same polymorphic &#x003b2;-adducin variant (Q529R) as MHS rats, the expression of proteins of podocyte slit membrane or foot process cytoskeleton (such as phospho-nephrin, synaptopodin, &#x003b1;-actinin, ZO-1, Fyn) is increased, while the urinary protein excretion was decreased. Therefore, the absence of &#x003b2;-adducin reduced the glomerular permeability to proteins. In contrast to erythrocytes [<xref ref-type="bibr" rid="CR20">20</xref>], &#x003b2;-adducin deletion did not induce a loss of &#x003b1;-adducin in glomeruli. (3) In congenic rats, the decreased expression of key podocyte proteins (such as nephrin, synaptopodin, &#x003b1;-actinin, ZO-1, podocin, Fyn), followed by an increase of urinary protein excretion and glomerular damage, traveled together with the DNA segment containing the &#x003b2;-adducin polymorphism of MHS rats. This effect was blunted by the simultaneous presence of MHS &#x003b1;-adducin. The epistatic interaction between &#x003b1;- and &#x003b2;-adducin suggests that the glomerular changes observed here were very likely due to the adducin variations. (4) In human IgAN, the rate of renal function decline increased when a specific combination of &#x003b1;- and &#x003b2;-adducin polymorphisms was present. Taken together, these observations strongly support the notion that &#x003b1;&#x003b2;-adducin heterodimers are involved in the molecular mechanisms underlying the process of glomerular permeability, associated with an increase of protein excretion and progression rate of glomerular failure.</p><p>In human IgAN, &#x003b2;-adducin polymorphism was associated to renal function decline, but not to the average urinary protein excretion, at least during the first 2&#x000a0;years after diagnosis. It is not clear whether this discrepancy with the rodent findings is real or due to the complexity of the human condition. In fact, in the human study, 47% of patients were on ACEI or other antihypertensive treatment. Renin&#x02013;angiotensin system inhibition may differently affect proteinuria and progression toward renal failure [<xref ref-type="bibr" rid="CR32">32</xref>] and may also differ across genotypes. In fact, the reduction of proteinuria associated to ACEI treatment was significant only in carriers of mutant ADD1 460Trp or ADD2 1797T alleles. It is worth mentioning that the cell surface expression of ACE is greater in human cultured fibroblasts carrying the ADD1 Trp allele, or in renal cells transfected with the ADD1 Trp allele, than in fibroblasts carrying the ADD1 Gly allele, or renal cells transfected with the ADD1 Gly allele [<xref ref-type="bibr" rid="CR33">33</xref>]. These observations, taken together with the larger genetic heterogeneity of humans as compared to that of inbred strains of rodents and the difference in the adducin mutation sites, may account for the discrepancy between humans and rodents on the genotype&#x02013;proteinuria relationship.</p><p>Nephrin is an essential component of the glomerular podocyte junction [<xref ref-type="bibr" rid="CR34">34</xref>] and participates to the formation of the glomerular filtration barrier via interactions with associated proteins, including the Src family protein kinase Fyn [<xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>]. Engagement of the nephrin ectodomain induces Fyn activation that favors nephrin phosphorylation [<xref ref-type="bibr" rid="CR35">35</xref>] and the recruitment of adaptor proteins, such as Nck, involved in the regulation of podocyte junction formation and actin cytoskeletal dynamics [<xref ref-type="bibr" rid="CR36">36</xref>]. Mutations of several podocyte proteins, or the knockout of Fyn or nephrin in mice, induce a rearrangement of the actin cytoskeleton and the disruption of the filtration barrier leading to renal disease [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR36">36</xref>].</p><p>Recently, also &#x003b2;-adducin has been shown to be a specific target of Fyn [<xref ref-type="bibr" rid="CR37">37</xref>]. Fyn binds and phosphorylates &#x003b2;-adducin at Tyr<sup>489</sup>, permitting its association with Fyn-SH<sub>2</sub> domain and translocation to the plasma membrane [<xref ref-type="bibr" rid="CR37">37</xref>]. Interestingly, the polymorphism (Q529R) identified in the rat &#x003b2;-adducin C-terminal domain maps close to the Fyn-dependent phosphorylation residue (Tyr<sup>489</sup>).</p><p>The data presented here in &#x003b2;-adducin null mice and congenic rats support the hypothesis that &#x003b2;-adducin may induce a reduction of Fyn protein expression on the cell membrane resulting in a downregulation of phosphorylated nephrin and related podocyte proteins, such as synaptopodin, ZO-1, and &#x003b1;-actinin, associated with the appearance of glomerular podocyte damage and proteinuria. Conversely, the knockout of the &#x003b2;-adducin gene in mice, or the presence of the polymorphic &#x003b1;-adducin variant in MHS, NA, or NAB rat substrains, seems to be protective. This effect appears to occur through the reactivation of the nephrin signaling pathway.</p><p><bold>Limitations</bold> As a first point, with regards to the human studies, one should keep in mind that we used the Cockcroft&#x02013;Gault formula to estimate the glomerular filtration rate. Though a suboptimal indicator, this formula is of practical use because it provides a quantitative estimate of the milliliters per minute loss of renal function in relation to the variables considered. Another note of caution concerns serum creatinine assay. Although creatinine had not been assayed by a unique unit, we respected center consistency, since each patient referred to his/her referring center that was using the same intracenter standards. A number of questions remain, however, unanswered. We have attempted to ascertain an association between a variety of genetic manipulations of adducin and the glomerular phenotypes. These include precise gene manipulations, like the knockout in mice, the introgression of DNA segments containing the adducin loci from one inbreed rat strain to another and genetic association studies in humans. Certainly, the introgression of a DNA segment, harboring other genes besides adducin [<xref ref-type="bibr" rid="CR21">21</xref>], cannot exclude their influence on our findings. However, this weakness is tempered by the interaction between &#x003b1;- and &#x003b2;-adducin DNA segments. In fact, the possibility that the other genes, mapping in close vicinity to the adducin locus in the DNA fragment, display such an interaction on the phenotypes we have measured is unlikely in view of the biochemical requirement that &#x003b1;- and &#x003b2;-adducin function as heterodimers [<xref ref-type="bibr" rid="CR6">6</xref>] and that both subunits are present in podocytes.</p><p>As in all the other studies aimed at establishing a putative relationship between a given gene variation and complex phenotypes, like progression of renal failure or proteinuria, when we change the context, we increase the number of confounding factors (such as variations in the genetic and environmental backgrounds) that may differently modulate the effect of the gene variants of interest. Therefore, we may anticipate some differences in the phenotype effect. Moreover, in our case, adducin mutations occur at different positions in rats and humans. In spite of the very high identity between the adducin of the two species (92%) and the many protein function similarities between rat and human mutant variants [<xref ref-type="bibr" rid="CR10">10</xref>], the difference in the mutation site may produce protein function variations that may differ across species.</p><p><bold>Conclusions</bold> Genetic studies involve two major steps: (1) to demonstrate that a given gene is involved in the regulation of a phenotype and leads to disease (in our case, adducin and glomerular permeability) and (2) to define the mechanistic steps linking these gene variations to the clinical phenotypes. While we believe we have provided solid data to support the first step, the second one will require further investigation to explore the mechanism underlying the reduction of podocyte proteins that, in turn, affects the glomerular permeability to proteins.</p><p>The wide range of contexts explored here strengthens the conclusion that &#x003b1;- and &#x003b2;-adducins are involved in glomerular disease. We may speculate that the magnitude of the adducin polymorphism impact on glomerular disease of the individual patient may be modest, or more severe, according to the individual genetic&#x02013;environmental background. Certainly, adducin genetic variants seem to exert a modifier rather than a triggering role within the heterogeneous network of the other podocyte gene polymorphisms.</p></sec><sec sec-type="supplementary-material"><sec id="AppESM1"><title>Electronic supplementary materials</title><supplementary-material id="d28e2292" content-type="local-data"><p>Below is the link to the electronic supplementary material. </p><media xlink:href="109_2009_549_MOESM1_ESM.pdf" id="MOESM1" mimetype="application" mime-subtype="pdf"><caption><p>ESMpdf1 (PDF 5222 kb)</p></caption></media></supplementary-material></sec></sec></body><back><ack><title>Acknowledgment</title><p>We thank Prof. D. Kerjaschki, Department of Pathology, Medical University of Vienna, for help in immunogold electron microscopy and Dr A. Corbelli for electron microscopy studies. The authors (MF, IM, CC, FP, FP) are Prassis sigma-tau employees and (GB) is a Prassis sigma-tau consultant.</p><p><bold>Fundings</bold> This study was supported in part by a grant from the Telethon Foundation EC 861, FIRB2003 research grant RBLA038RMA-010 from the Italian Ministry of University and Scientific Research, by Ingenious Hypercare LSHM-CT-2006-037093 (DC), by HYPERGENES grant HEALTH-F4-2007-201550 (DC), and by National Institutes of Health, grant 1 R01 HL075714 (LLP).</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiggins</surname><given-names>RC</given-names></name></person-group><article-title>The spectrum of podocytopathies: a unifying view of glomerular disease</article-title><source>Kidney Int</source><year>2007</year><volume>71</volume><fpage>1205</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5002222</pub-id><pub-id pub-id-type="pmid">17410103</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aaltonen</surname><given-names>P</given-names></name><name><surname>Holthofer</surname><given-names>H</given-names></name></person-group><article-title>Nephrin and related proteins in the pathogenesis of nephropathy</article-title><source>Drug Discov Today Dis Mech</source><year>2007</year><volume>4</volume><fpage>21</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.ddmec.2007.06.003</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathieson</surname><given-names>PW</given-names></name></person-group><article-title>Podocyte-specific gene mutations are coming of age</article-title><source>J Am Soc Nephrol</source><year>2008</year><volume>19</volume><fpage>190</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1681/ASN.2007121341</pub-id><pub-id pub-id-type="pmid">18216304</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinkes</surname><given-names>B</given-names></name><name><surname>Vlangos</surname><given-names>C</given-names></name><name><surname>Heeringa</surname><given-names>S</given-names></name><name><surname>Mucha</surname><given-names>B</given-names></name><name><surname>Gbadegesin</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Hasselbacher</surname><given-names>K</given-names></name><name><surname>Ozaltin</surname><given-names>F</given-names></name><name><surname>Hildebrandt</surname><given-names>F</given-names></name><collab>APN Study Group</collab></person-group><article-title>Specific podocin mutations correlate with age of onset in steroid-resistant nephrotic syndrome</article-title><source>J Am Soc Nephrol</source><year>2008</year><volume>19</volume><fpage>365</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1681/ASN.2007040452</pub-id><pub-id pub-id-type="pmid">18216321</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tipping</surname><given-names>PG</given-names></name></person-group><article-title>Are podocytes passive or provocative in proteinuric glomerular pathology?</article-title><source>J Am Soc Nephrol</source><year>2008</year><volume>19</volume><fpage>651</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1681/ASN.2008020156</pub-id><pub-id pub-id-type="pmid">18322155</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuoka</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Bennett</surname><given-names>V</given-names></name></person-group><article-title>Adducin: structure, function and regulation</article-title><source>Cell Mol Life Sci</source><year>2000</year><volume>57</volume><fpage>884</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1007/PL00000731</pub-id><pub-id pub-id-type="pmid">10950304</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripodi</surname><given-names>G</given-names></name><name><surname>Valtorta</surname><given-names>F</given-names></name><name><surname>Torielli</surname><given-names>L</given-names></name><name><surname>Chieregatti</surname><given-names>E</given-names></name><name><surname>Salardi</surname><given-names>S</given-names></name><name><surname>Trusolino</surname><given-names>L</given-names></name><name><surname>Menegon</surname><given-names>A</given-names></name><name><surname>Ferrari</surname><given-names>P</given-names></name><name><surname>Marchisio</surname><given-names>PC</given-names></name><name><surname>Bianchi</surname><given-names>G</given-names></name></person-group><article-title>Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport</article-title><source>J Clin Invest</source><year>1996</year><volume>97</volume><fpage>2815</fpage><lpage>2822</lpage><pub-id pub-id-type="doi">10.1172/JCI118737</pub-id><pub-id pub-id-type="pmid">8675693</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianchi</surname><given-names>G</given-names></name><name><surname>Tripodi</surname><given-names>G</given-names></name><name><surname>Casari</surname><given-names>G</given-names></name><name><surname>Salardi</surname><given-names>S</given-names></name><name><surname>Barber</surname><given-names>BR</given-names></name><name><surname>Garcia</surname><given-names>R</given-names></name><name><surname>Leoni</surname><given-names>P</given-names></name><name><surname>Torielli</surname><given-names>L</given-names></name><name><surname>Cusi</surname><given-names>D</given-names></name><name><surname>Ferrandi</surname><given-names>M</given-names></name><name><surname>Pinna</surname><given-names>LA</given-names></name><name><surname>Baralle</surname><given-names>FE</given-names></name><name><surname>Ferrari</surname><given-names>P</given-names></name></person-group><article-title>Two point mutations within the adducin genes are involved in blood pressure variation</article-title><source>Proc Natl Acad Sci</source><year>1994</year><volume>91</volume><fpage>3999</fpage><lpage>4003</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.9.3999</pub-id><pub-id pub-id-type="pmid">8171025</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cusi</surname><given-names>D</given-names></name><name><surname>Barlassina</surname><given-names>C</given-names></name><name><surname>Azzani</surname><given-names>T</given-names></name><name><surname>Casari</surname><given-names>G</given-names></name><name><surname>Citterio</surname><given-names>L</given-names></name><name><surname>Devoto</surname><given-names>M</given-names></name><name><surname>Glorioso</surname><given-names>N</given-names></name><name><surname>Lanzani</surname><given-names>C</given-names></name><name><surname>Manunta</surname><given-names>P</given-names></name><name><surname>Righetti</surname><given-names>M</given-names></name><name><surname>Rivera</surname><given-names>R</given-names></name><name><surname>Stella</surname><given-names>P</given-names></name><name><surname>Troffa</surname><given-names>C</given-names></name><name><surname>Zagato</surname><given-names>L</given-names></name><name><surname>Bianchi</surname><given-names>G</given-names></name></person-group><article-title>Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension</article-title><source>Lancet</source><year>1997</year><volume>349</volume><fpage>1353</fpage><lpage>1357</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(97)01029-5</pub-id><pub-id pub-id-type="pmid">9149697</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianchi</surname><given-names>G</given-names></name></person-group><article-title>Genetic variations of tubular sodium reabsorption leading to &#x0201c;primary&#x0201d; hypertension: from gene polymorphism to clinical symptoms</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><year>2005</year><volume>289</volume><fpage>R1536</fpage><lpage>R1549</lpage><pub-id pub-id-type="pmid">16278339</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manunta</surname><given-names>P</given-names></name><name><surname>Lavery</surname><given-names>G</given-names></name><name><surname>Lanzani</surname><given-names>C</given-names></name><name><surname>Braund</surname><given-names>PS</given-names></name><name><surname>Simonini</surname><given-names>M</given-names></name><name><surname>Bodycote</surname><given-names>C</given-names></name><name><surname>Zagato</surname><given-names>L</given-names></name><name><surname>Delli Carpini</surname><given-names>S</given-names></name><name><surname>Tantardini</surname><given-names>C</given-names></name><name><surname>Brioni</surname><given-names>E</given-names></name><name><surname>Bianchi</surname><given-names>G</given-names></name><name><surname>Samani</surname><given-names>NJ</given-names></name></person-group><article-title>Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation</article-title><source>Hypertension</source><year>2008</year><volume>52</volume><fpage>366</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.108.113977</pub-id><pub-id pub-id-type="pmid">18591455</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staessen</surname><given-names>JA</given-names></name><name><surname>Wang</surname><given-names>JG</given-names></name><name><surname>Brand</surname><given-names>E</given-names></name><name><surname>Barlassina</surname><given-names>C</given-names></name><name><surname>Birkenh&#x000e4;ger</surname><given-names>WH</given-names></name><name><surname>Herrmann</surname><given-names>SM</given-names></name><name><surname>Fagard</surname><given-names>R</given-names></name><name><surname>Tizzoni</surname><given-names>L</given-names></name><name><surname>Bianchi</surname><given-names>G</given-names></name></person-group><article-title>Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population</article-title><source>J Hypertens</source><year>2001</year><volume>19</volume><fpage>1349</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1097/00004872-200108000-00002</pub-id><pub-id pub-id-type="pmid">11518842</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JG</given-names></name><name><surname>Staessen</surname><given-names>JA</given-names></name><name><surname>Tizzoni</surname><given-names>L</given-names></name><name><surname>Brand</surname><given-names>E</given-names></name><name><surname>Birkenh&#x000e4;ger</surname><given-names>WH</given-names></name><name><surname>Fagard</surname><given-names>R</given-names></name><name><surname>Herrmann</surname><given-names>SM</given-names></name><name><surname>Bianchi</surname><given-names>G</given-names></name></person-group><article-title>Renal function in relation to three candidate genes</article-title><source>Am J Kidney Dis</source><year>2001</year><volume>38</volume><fpage>1158</fpage><lpage>1168</lpage><pub-id pub-id-type="doi">10.1053/ajkd.2001.29205</pub-id><pub-id pub-id-type="pmid">11728946</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicod</surname><given-names>J</given-names></name><name><surname>Frey</surname><given-names>BM</given-names></name><name><surname>Frey</surname><given-names>FJ</given-names></name><name><surname>Ferrari</surname><given-names>P</given-names></name></person-group><article-title>Role of the alpha-adducin genotype on renal disease progression</article-title><source>Kidney Int</source><year>2002</year><volume>61</volume><fpage>1270</fpage><lpage>1275</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2002.00275.x</pub-id><pub-id pub-id-type="pmid">11918733</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narita</surname><given-names>I</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name><name><surname>Saito</surname><given-names>N</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Ajiro</surname><given-names>J</given-names></name><name><surname>Sato</surname><given-names>F</given-names></name><name><surname>Saga</surname><given-names>D</given-names></name><name><surname>Kondo</surname><given-names>D</given-names></name><name><surname>Akazawa</surname><given-names>K</given-names></name><name><surname>Sakatsume</surname><given-names>M</given-names></name><name><surname>Gejyo</surname><given-names>F</given-names></name></person-group><article-title>Interaction between ACE and ADD1 gene polymorphisms in the progression of IgA nephropathy in Japanese patients</article-title><source>Hypertension</source><year>2003</year><volume>42</volume><fpage>304</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000085193.25617.78</pub-id><pub-id pub-id-type="pmid">12885793</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beeks</surname><given-names>E</given-names></name><name><surname>Klauw</surname><given-names>MM</given-names></name><name><surname>Kroon</surname><given-names>AA</given-names></name><name><surname>Spiering</surname><given-names>W</given-names></name><name><surname>Fuss-Lejeune</surname><given-names>MJ</given-names></name><name><surname>Leeuw</surname><given-names>PW</given-names></name></person-group><article-title>Alpha-adducin Gly460Trp polymorphism and renal hemodynamics in essential hypertension</article-title><source>Hypertension</source><year>2004</year><volume>44</volume><fpage>419</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000141410.72537.fd</pub-id><pub-id pub-id-type="pmid">15326084</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merta</surname><given-names>M</given-names></name><name><surname>Reiterov&#x000e1;</surname><given-names>J</given-names></name><name><surname>Stekrov&#x000e1;</surname><given-names>J</given-names></name><name><surname>Rysava</surname><given-names>R</given-names></name><name><surname>Rihov&#x000e1;</surname><given-names>Z</given-names></name><name><surname>Tesar</surname><given-names>V</given-names></name><name><surname>Viklick&#x000fd;</surname><given-names>O</given-names></name><name><surname>Kmentova</surname><given-names>D</given-names></name></person-group><article-title>Influence of the alpha-adducin and ACE gene polymorphism on the progression of autosomal-dominant polycystic kidney disease</article-title><source>Kidney Blood Press Res</source><year>2003</year><volume>26</volume><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1159/000069768</pub-id><pub-id pub-id-type="pmid">12697976</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Amico</surname><given-names>G</given-names></name></person-group><article-title>The commonest glomerulonephritis in the world: IgA nephropathy</article-title><source>Q J Med</source><year>1987</year><volume>64</volume><fpage>709</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">3329736</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackinnon</surname><given-names>B</given-names></name><name><surname>Fraser</surname><given-names>EP</given-names></name><name><surname>Cattran</surname><given-names>DC</given-names></name><name><surname>Fox</surname><given-names>JG</given-names></name><name><surname>Geddes</surname><given-names>CC</given-names></name></person-group><article-title>Validation of the Toronto formula to predict progression in IgA nephropathy</article-title><source>Nephron Clin Prac</source><year>2008</year><volume>109</volume><fpage>148</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1159/000145458</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilligan</surname><given-names>DM</given-names></name><name><surname>Lozovatsky</surname><given-names>L</given-names></name><name><surname>Gwynn</surname><given-names>B</given-names></name><name><surname>Brugnara</surname><given-names>C</given-names></name><name><surname>Mohandas</surname><given-names>N</given-names></name><name><surname>Peters</surname><given-names>LL</given-names></name></person-group><article-title>Targeted disruption of the beta adducin gene (Add2) causes red blood cell spherocytosis in mice</article-title><source>Proc Natl Acad Sci</source><year>1999</year><volume>96</volume><fpage>10717</fpage><lpage>10722</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.19.10717</pub-id><pub-id pub-id-type="pmid">10485892</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripodi</surname><given-names>G</given-names></name><name><surname>Florio</surname><given-names>M</given-names></name><name><surname>Ferrandi</surname><given-names>M</given-names></name><name><surname>Modica</surname><given-names>R</given-names></name><name><surname>Zimdahl</surname><given-names>H</given-names></name><name><surname>Hubner</surname><given-names>N</given-names></name><name><surname>Ferrari</surname><given-names>P</given-names></name><name><surname>Bianchi</surname><given-names>G</given-names></name></person-group><article-title>Effect of Add1 gene transfer on blood pressure in reciprocal congenic strains of Milan rats</article-title><source>Biochem Biophys Res Commun</source><year>2004</year><volume>324</volume><fpage>562</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2004.09.079</pub-id><pub-id pub-id-type="pmid">15474463</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regele</surname><given-names>HM</given-names></name><name><surname>Fillipovic</surname><given-names>E</given-names></name><name><surname>Langer</surname><given-names>B</given-names></name><name><surname>Poczewki</surname><given-names>H</given-names></name><name><surname>Kraxberger</surname><given-names>I</given-names></name><name><surname>Bittner</surname><given-names>RE</given-names></name><name><surname>Kerjaschki</surname><given-names>D</given-names></name></person-group><article-title>Glomerular expression of dystroglycans is reduced in minimal change nephrosis but not in focal segmental glomerulosclerosis</article-title><source>J Am Soc Nephrol</source><year>2000</year><volume>11</volume><fpage>403</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">10703664</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartosik</surname><given-names>LP</given-names></name><name><surname>Lajoie</surname><given-names>G</given-names></name><name><surname>Sugar</surname><given-names>L</given-names></name><name><surname>Cattran</surname><given-names>DC</given-names></name></person-group><article-title>Predicting progression in IgA nephropathy</article-title><source>Am J Kidney Dis</source><year>2001</year><volume>38</volume><fpage>728</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1053/ajkd.2001.27689</pub-id><pub-id pub-id-type="pmid">11576875</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cockcroft</surname><given-names>DW</given-names></name><name><surname>Gault</surname><given-names>MH</given-names></name></person-group><article-title>Prediction of creatinine clearance from serum creatinine</article-title><source>Nephron</source><year>1976</year><volume>16</volume><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1159/000180580</pub-id><pub-id pub-id-type="pmid">1244564</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Amico</surname><given-names>G</given-names></name><name><surname>Ragni</surname><given-names>A</given-names></name><name><surname>Gandini</surname><given-names>E</given-names></name><name><surname>Fellin</surname><given-names>G</given-names></name></person-group><article-title>Typical and atypical natural history of IgA nephropathy in adult patients</article-title><source>Contrib Nephrol</source><year>1993</year><volume>104</volume><fpage>6</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">8325035</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SM</given-names></name><name><surname>Rao</surname><given-names>VM</given-names></name><name><surname>Franklin</surname><given-names>WA</given-names></name><name><surname>Schiffer</surname><given-names>MS</given-names></name><name><surname>Aronson</surname><given-names>AJ</given-names></name><name><surname>Spargo</surname><given-names>BH</given-names></name><name><surname>Katz</surname><given-names>AI</given-names></name></person-group><article-title>IgA nephropathy: morphologic predictors of progressive renal disease</article-title><source>Hum Pathol</source><year>1982</year><volume>13</volume><fpage>314</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1016/S0046-8177(82)80221-9</pub-id><pub-id pub-id-type="pmid">7076216</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JG</given-names></name><name><surname>Staessen</surname><given-names>JA</given-names></name><name><surname>Barlassina</surname><given-names>C</given-names></name><name><surname>Fagard</surname><given-names>R</given-names></name><name><surname>Kuznetsova</surname><given-names>T</given-names></name><name><surname>Struijker-Boudier</surname><given-names>HA</given-names></name><name><surname>Zagato</surname><given-names>L</given-names></name><name><surname>Citterio</surname><given-names>L</given-names></name><name><surname>Messaggio</surname><given-names>E</given-names></name><name><surname>Bianchi</surname><given-names>G</given-names></name></person-group><article-title>Association between hypertension and variation in the &#x003b1;- and &#x003b2;-adducin genes in a white population</article-title><source>Kidney Int</source><year>2002</year><volume>62</volume><fpage>2152</fpage><lpage>2159</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2002.00691.x</pub-id><pub-id pub-id-type="pmid">12427140</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Neter</surname><given-names>J</given-names></name><name><surname>Wasserman</surname><given-names>W</given-names></name><name><surname>Kutner</surname><given-names>MH</given-names></name></person-group><source>Applied linear statistical models</source><year>1985</year><edition>2</edition><publisher-loc>Homewood</publisher-loc><publisher-name>Irwin</publisher-name></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandis</surname><given-names>A</given-names></name><name><surname>Bianchi</surname><given-names>G</given-names></name><name><surname>Reale</surname><given-names>E</given-names></name><name><surname>Helmchen</surname><given-names>U</given-names></name><name><surname>K&#x000fc;hn</surname><given-names>K</given-names></name></person-group><article-title>Age-dependent glomerulosclerosis and proteinuria occurring in rats of the Milan normotensive strain and not in rats of the Milan hypertensive strain</article-title><source>Lab Invest</source><year>1986</year><volume>55</volume><fpage>234</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">3736022</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pugliese</surname><given-names>G</given-names></name><name><surname>Ricci</surname><given-names>C</given-names></name><name><surname>Iacobini</surname><given-names>C</given-names></name><name><surname>Menini</surname><given-names>S</given-names></name><name><surname>Fioretto</surname><given-names>P</given-names></name><name><surname>Ferrandi</surname><given-names>M</given-names></name><name><surname>Giardino</surname><given-names>LA</given-names></name><name><surname>Armelloni</surname><given-names>S</given-names></name><name><surname>Mattinzoli</surname><given-names>D</given-names></name><name><surname>Rastaldi</surname><given-names>MP</given-names></name><name><surname>Pugliese</surname><given-names>F</given-names></name></person-group><article-title>Glomerular barrier dysfunction in glomerulosclerosis-resistant Milan rats with experimental diabetes: the role of renal haemodynamics</article-title><source>J Pathol</source><year>2007</year><volume>213</volume><fpage>210</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1002/path.2226</pub-id><pub-id pub-id-type="pmid">17768702</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pugliese</surname><given-names>F</given-names></name><name><surname>Mene&#x02019;</surname><given-names>P</given-names></name><name><surname>Cinotti</surname><given-names>GA</given-names></name></person-group><article-title>Glomerular prostaglandins and thromboxane synthesis in normotensive and hypertensive rats of the Milan strain before and after development of hypertension</article-title><source>J Hypertension</source><year>1986</year><volume>4</volume><fpage>S391</fpage><lpage>S393</lpage></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>JF</given-names></name><name><surname>Schmieder</surname><given-names>RE</given-names></name><name><surname>McQueen</surname><given-names>M</given-names></name><name><surname>Dyal</surname><given-names>L</given-names></name><name><surname>Schumacher</surname><given-names>H</given-names></name><name><surname>Pogue</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Maggioni</surname><given-names>A</given-names></name><name><surname>Budaj</surname><given-names>A</given-names></name><name><surname>Chaithiraphan</surname><given-names>S</given-names></name><name><surname>Dickstein</surname><given-names>K</given-names></name><name><surname>Keltai</surname><given-names>M</given-names></name><name><surname>Mets&#x000e4;rinne</surname><given-names>K</given-names></name><name><surname>Oto</surname><given-names>A</given-names></name><name><surname>Parkhomenko</surname><given-names>A</given-names></name><name><surname>Piegas</surname><given-names>LS</given-names></name><name><surname>Svendsen</surname><given-names>TL</given-names></name><name><surname>Teo</surname><given-names>KK</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name></person-group><article-title>Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>547</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)61236-2</pub-id><pub-id pub-id-type="pmid">18707986</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zagato</surname><given-names>L</given-names></name><name><surname>Kuznetsova</surname><given-names>T</given-names></name><name><surname>Tripodi</surname><given-names>G</given-names></name><name><surname>Zerbini</surname><given-names>G</given-names></name><name><surname>Richart</surname><given-names>T</given-names></name><name><surname>Thijs</surname><given-names>L</given-names></name><name><surname>Manunta</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>JG</given-names></name><name><surname>Bianchi</surname><given-names>G</given-names></name><name><surname>Staessen</surname><given-names>JA</given-names></name></person-group><article-title>Angiotensin-converting enzyme I/D and alpha-adducin Gly460Trp polymorphisms: from angiotensin-converting enzyme activity to cardiovascular outcome</article-title><source>Hypertension</source><year>2007</year><volume>49</volume><fpage>1291</fpage><lpage>1297</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.106.085498</pub-id><pub-id pub-id-type="pmid">17452507</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faul</surname><given-names>C</given-names></name><name><surname>Asanuma</surname><given-names>K</given-names></name><name><surname>Yanagida-Asanuma</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Mundel</surname><given-names>P</given-names></name></person-group><article-title>Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton</article-title><source>Trends Cell Biol</source><year>2007</year><volume>17</volume><fpage>428</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2007.06.006</pub-id><pub-id pub-id-type="pmid">17804239</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>R</given-names></name><name><surname>Kovari</surname><given-names>I</given-names></name><name><surname>Soofi</surname><given-names>A</given-names></name><name><surname>Nihalani</surname><given-names>D</given-names></name><name><surname>Patrie</surname><given-names>K</given-names></name><name><surname>Holzman</surname><given-names>LB</given-names></name></person-group><article-title>Nephrin ectodomain engagement results in Src kinase activation, nephrin phosphorylation, Nck recruitment, and actin polymerization</article-title><source>J Clin Invest</source><year>2006</year><volume>116</volume><fpage>1346</fpage><lpage>1359</lpage><pub-id pub-id-type="doi">10.1172/JCI27414</pub-id><pub-id pub-id-type="pmid">16543952</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>N</given-names></name><name><surname>Blasutig</surname><given-names>IM</given-names></name><name><surname>Eremina</surname><given-names>V</given-names></name><name><surname>Ruston</surname><given-names>JM</given-names></name><name><surname>Bladt</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Larose</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>SS</given-names></name><name><surname>Takano</surname><given-names>T</given-names></name><name><surname>Quaggin</surname><given-names>SE</given-names></name><name><surname>Pawson</surname><given-names>T</given-names></name></person-group><article-title>Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes</article-title><source>Nature</source><year>2006</year><volume>440</volume><fpage>818</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1038/nature04662</pub-id><pub-id pub-id-type="pmid">16525419</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotoh</surname><given-names>H</given-names></name><name><surname>Okumura</surname><given-names>N</given-names></name><name><surname>Yagi</surname><given-names>T</given-names></name><name><surname>Okumura</surname><given-names>A</given-names></name><name><surname>Shima</surname><given-names>T</given-names></name><name><surname>Nagai</surname><given-names>K</given-names></name></person-group><article-title>Fyn-induced phosphorylation of beta-adducin at tyrosine 489 and its role in their subcellular localization</article-title><source>Biochem Biophys Res Commun</source><year>2006</year><volume>346</volume><fpage>600</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2006.05.167</pub-id><pub-id pub-id-type="pmid">16765915</pub-id></mixed-citation></ref></ref-list><fn-group><fn><p>Mara Ferrandi and Daniele Cusi contributed equally to this study.</p></fn></fn-group></back></article>